罗格列酮对2型糖尿病患者血清炎症递质的影响.docVIP

维普资讯htp:/www.qipcom · 1145 · · 论 著 · 罗格列酮对2型糖尿病患者血清炎症递质的影响 樊世江，谢辉 【摘要】 目的 探讨罗格列酮对2型糖尿病 (T2DM) 患者血清基质金属蛋白酶-9 (MMP-9)、C- 反应蛋白 (CRP) 和白介素-6 (IL-6) 的影响。方法 将150例 T2DM 患者随机分为3组：所有患者均控制饮食、适当运动、 采用胰岛素控制等一般对症治疗， A 组患者还给予安慰剂， B 组患者口服罗格列酮4 mg,C 组患者口服罗格列酮8 mg。 治疗前及治疗20周用酶联免疫吸附 (ELISA) 法测定3组患者血清CRP、IL-6 和 MMP-9 水平，并测量血脂等生化 指标。 结果 治疗后C 组患者血脂水平与A 组比较，差别有统计学意义 (P0.05);B 组患者血脂水平与 C 组比较， 差别无统计学意义 (P0.05)。B 组、C 组患者CRP、IL-6 和 MMP-9 水平与 A 组比较，差别均有统计学意义 (P 0.05);C 组患者血清CRP 和 MMP-9 水平与 B 组比较，差别有统计学意义 (P0.05), 而两组间IⅡ-6 水平差别 无统计学意义 (P0.05)。 结论 罗格列酮可减少炎症递质MMP-9、CRP 和Ⅱ-6水平，其抗炎作用在2型糖尿病 治疗中起作用。 【关键词】 罗格列酮；糖尿病，2型；基质金属蛋白酶-9; C- 反应蛋白，白介素-6 【中图分类号】 R587.1 【文献标识码】 A 【文章编号】1007-9572(2007)14-1145- 03 Effects of Rosiglitazone on Inflammatory Medium in Patients with Type 2 Diabetes Mellitus FAN Shi -jiang,XIE Hui. Peoples Hospital of Zhangjiajie,Zhangjiajie 427000,China 【Abstract】 Objective To investigate the effects of rosiglitazone on the serum matrix metallop roteinase-9(MMP- 9),C-reactive protein(CRP)and IL-6 in patients with type 2 diabetes patients. Methods Type 2 diabetic patients were devided randomly into three groups; Group A is insulin treatment group, groug B is 4 mg rosiglitazone and insulin treatment group, and group C is 8 mg rosiglitazone and insulin treatment group. The serum MMP-9,CRP and IL-6 in three groups were detectec by ELISA. Results There were significant differences in the serum lipid level between group A and group C(P 0.05),but there were no significant differences between group B and group C(P0.05). The serum CRP,IL-6 and MMP -9 level in group B and group C decreased more significantly than those in group A(P0.05). There were significant differ- ences in CRP and MMP-9 level between group B and group C(P0.05),but there was no difference in the IL-6 level be- tween group B and group C(P0.05). Conclusion Rosiglitazone can reduce the level of MMP-9,CRP and IL-6,its anti - inflam